Rosemary Harrison compensation by year
TCR2 THERAPEUTICS Summary Compensation Table · the one fiscal year held| Component | FY2022 |
|---|---|
| Salary | $372,083 |
| Bonus | $0 |
| Stock awards | $12,437 |
| Option awards | $531,582 |
| Non-equity incentive | $140,000 |
| Pension and deferred compensation | $0 |
| All other | $10,461 |
| Total | $1,066,563 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TCR2 THERAPEUTICS INC. 10-K filed March 23, 2023, accession 0000950170-23-009312, and prior-year filings. Open the filing on EDGAR.
How this page was built: the TCR2 THERAPEUTICS INC. filed document, accession 0000950170-23-009312. Every figure is read from that document and cited to the page and table it appears in. Filed March 23, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 46,597 | $46,597 | — |
| TVA | — | $12,882 | — |
| RSU | 12,882 | $12,882 | — |
| Option | 76,930 | — | $0.97 |
| Option | 191,102 | — | $4.04 |
Per the Outstanding Equity Awards at Fiscal Year-End table in TCR2 THERAPEUTICS INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
TCR2 THERAPEUTICS’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Garry Menzel | President and Chief Executive Officer | $1,744,815 |
| Rosemary Harrison · this page | Chief Business & Strategy Officer | $1,066,563 |
| Alfonso Cardama | Chief Medical Officer | $1,012,109 |
The full TCR2 THERAPEUTICS compensation record
free company briefThis page is one person within TCR2 THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TCR2 THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.